{'output': [['Agios Pharmaceuticals Inc.', 'COMP', 'Outline', 'Key 2018 Priorities', 'CONCEPT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Expand', 'Clinical And Research Programs', 'CONCEPT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Drive', 'Long Term Value', 'CONCEPT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Submit', 'Seventh Ind Submission For A Dhodh Inhibitor', 'PRODUCT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Treat', 'Hematologic Malignancies', 'CONCEPT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Have', 'Cash, Cash Equivalents & Marketable Securities', 'ECON_INDICATOR'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Funds', 'Clinical & Research Programs', 'CONCEPT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Activate-T', 'Pivotal Trial In Pyruvate Kinase Deficiency With Ag-348', 'PRODUCT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Activate', 'Pivotal Trial In Pyruvate Kinase Deficiency With Ag-348', 'PRODUCT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Plan', 'Phase 2 Proof Of Concept Trial Of Ag-348 In Thalassemia', 'CONCEPT'], ['Agios Pharmaceuticals Inc.', 'COMP', 'Enter', 'Phase 1 Dose-Escalation Trial In Mtap-Deleted Tumors With Ag-270', 'PRODUCT']]}